Reactivity of Two Major Allergens Isolated from Schistosoma japonicum Eggs against IgE and IgG Antibodies in Human Serum

1987 ◽  
Vol 83 (2) ◽  
pp. 213-216 ◽  
Author(s):  
Makoto Owhashi ◽  
Yoichiro Horii ◽  
Akira Ishii ◽  
Yukifumi Nawa
Keyword(s):  
Human Serum ◽  
Schistosoma Japonicum ◽  
Igg Antibodies ◽  
Major Allergens

scholarly journals Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum.

1986 ◽  
Vol 164 (5) ◽  
pp. 1735-1748 ◽  
Author(s):  
P A Rice ◽  
H E Vayo ◽  
M R Tam ◽  
M S Blake
Keyword(s):  
Membrane Protein ◽  
Neisseria Gonorrhoeae ◽  
Human Serum ◽  
Outer Membrane ◽  
Outer Membrane Protein ◽  
Immune Serum ◽  
Igg Antibodies ◽  
Porin Protein ◽  
Blocking Activity ◽  
Normal Human

Neisseria gonorrhoeae that resist complement-dependent killing by normal human serum (NHS) are sometimes killed by immune convalescent serum from patients recovering from disseminated gonococcal infection (DGI). In these studies, killing by immune serum was prevented or blocked by IgG isolated from NHS. Purified human IgG antibodies directed against gonococcal protein III, an antigenically conserved outer membrane protein, contained most of the blocking activity in IgG. Antibodies specific for gonococcal porin (protein I), the major outer membrane protein, displayed no blocking function. In separate experiments, immune convalescent DGI serum which did not exhibit bactericidal activity was restored to killing by selective depletion of protein III antibodies by immunoabsorption. These studies indicate that protein III antibodies in normal and immune human serum play a role in serum resistance of N. gonorrhoeae.

scholarly journals Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides

mSphere ◽  
2018 ◽  
Vol 3 (4) ◽  
pp. e00128-18 ◽  
Author(s):  
Danka Pavliakova ◽  
Peter C. Giardina ◽  
Soraya Moghazeh ◽  
Shite Sebastian ◽  
Maya Koster ◽  
...  
Keyword(s):  
Human Serum ◽  
Lower Limit ◽  
Immunosorbent Assay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Correlate Of Protection ◽  
Immune Correlate ◽  
Relative Standard ◽  
Limit Of Quantitation

ABSTRACT A Luminex-based direct immunoassay (dLIA) platform has been developed to replace the standardized pneumococcal enzyme-linked immunosorbent assay platform. The multiplex dLIA simultaneously measures the concentration of serum immunoglobulin G (IgG) antibodies specific for pneumococcal capsular polysaccharide (PnPS) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The assay uses poly-l-lysine (PLL)-conjugated PnPS, chemically coupled to spectrally distinct Luminex microspheres. Assay validation experiments were performed using residual human serum samples obtained from 13-valent pneumococcal conjugate vaccine (13vPnC) clinical studies. Assay results are expressed as IgG antibody concentrations in micrograms per milliliter using the international reference serum, 007sp. The lower limit of quantitation (LLOQ) for all serotypes covered in the 13-plex dLIA fell within the range of 0.002 to 0.038 µg/ml serum IgG. The difference between the lower limit and upper limit of the assay range was >500-fold for all serotypes, and assay variability was <20% relative standard deviation (RSD) for all serotypes. IgG antibody measurements were shown to be serotype-specific (some cross-reactivity was observed only between the structurally related serotypes 6A and 6B as well as 19A and 19F), and no interference was observed between the serotypes when the assay was performed in the 13-plex format compared to the singleplex assays. The 13-plex dLIA platform developed by Pfizer Inc. generates up to 143 test results in a single 96-well plate and is a suitable replacement of the enzyme-linked immunosorbent assay (ELISA) platform for evaluating vaccine clinical trials. IMPORTANCE The pneumococcal enzyme-linked immunosorbent assay (ELISA) measures IgG antibodies in human serum, and it is an important assay that supports licensure of pneumococcal vaccines. The immune correlate of protection, 0.35 µg/ml of IgG antibodies, was determined by the ELISA method. Pfizer has developed a new Luminex-based assay platform to replace the ELISA. These papers describe the important work of (i) validating the Luminex-based assay and (ii) bridging the immune correlate of protection (0.35 µg/ml IgG) to equivalent values reported by the Luminex platform.

Quantitative Binding Assay for Measuring Specific IgG Antibodies to Alpha-Gal Using the Neoglycoprotein Gal-α-1,3-Gal-β-1,4-Glcnac-Human Serum Albumin

2015 ◽  
Vol 135 (2) ◽  
pp. AB188
Author(s):  
Alexander J. Schuyler ◽  
Hayley R. James ◽  
Theo Rispens ◽  
Lisa J. Workman ◽  
Matthew S. Perzanowski ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Binding Assay ◽  
Igg Antibodies ◽  
Specific Igg ◽  
Specific Igg Antibodies

Magnetic microbead-based enzyme-linked immunoassay for detection of Schistosoma japonicum antibody in human serum

2010 ◽  
Vol 404 (2) ◽  
pp. 127-134 ◽  
Author(s):  
Zhenshi Liu ◽  
Li Zhang ◽  
Hai Yang ◽  
Yanhong Zhu ◽  
Wei Jin ◽  
...  
Keyword(s):  
Human Serum ◽  
Schistosoma Japonicum ◽  
Magnetic Microbead

scholarly journals Performance of three SARS-CoV-2 immunoassays, three rapid lateral flow tests and a novel bead-based affinity surrogate test for the detection of SARS-CoV-2 antibodies in human serum

2021 ◽  
Author(s):  
Manuel Krone ◽  
Julia Gütling ◽  
Johannes Wagener ◽  
Thiên-Trí Lâm ◽  
Christoph Schoen ◽  
...  
Keyword(s):  
Human Serum ◽  
Sensitivity And Specificity ◽  
Symptom Onset ◽  
Gold Standard ◽  
Neutralizing Antibodies ◽  
Neutralization Test ◽  
Lateral Flow ◽  
Igg Antibodies ◽  
Serum Samples ◽  
Lateral Flow Tests

For the control of immunity in COVID-19 survivors and vaccinated subjects there is an urgent need for reliable and rapid serological assays. Based on samples from 63 COVID-19 survivors up to seven months after symptom onset, and on 50 serum samples taken before the beginning of the pandemic, we compared the performance of three commercial immunoassays for the detection of SARS-CoV-2 IgA and IgG antibodies (Euroimmun SARS-COV-2 IgA/IgG, Mikrogen recomWell SARS-CoV-2 IgA/IgG, and SERION ELISA agile SARS-CoV-2 IgA/IgG) and three rapid lateral flow (immunochromatographic) tests (Abbott Panbio COVID-19 IgG/IgM, NADAL COVID-19 IgG/IgM, and Cleartest Corona 2019-nCOV IgG/IgM) with a plaque-reduction neutralization test (PRNT50) representing the gold standard. Fifty-seven out of 63 PCR-confirmed COVID-19 patients (90%) showed neutralizing antibodies. The sensitivity of the seven assays ranged from 7.0% to 98.3%, the specificity from 86.0% to 100.0%. Only one commercial immunoassay showed a sensitivity and specificity of greater than 98%.

scholarly journals Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays

2020 ◽  
Vol 58 (9) ◽  
pp. 1601-1607 ◽  
Author(s):  
Chungen Qian ◽  
Mi Zhou ◽  
Fangming Cheng ◽  
Xiaotao Lin ◽  
Yijun Gong ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Human Serum ◽  
Normal Population ◽  
Laboratory Diagnosis ◽  
Hospitalized Patients ◽  
Nucleic Acid Testing ◽  
Igg Antibodies ◽  
Clinical Sensitivity ◽  
Specificity And Sensitivity ◽  
Assay Precision

AbstractObjectivesThe outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally. The laboratory diagnosis of SARS-CoV-2 infection has relied on nucleic acid testing; however, it has some limitations, such as low throughput and high rates of false negatives. Tests of higher sensitivity are needed to effectively identify infected patients.MethodsThis study has developed fully automated chemiluminescent immunoassays to determine IgM and IgG antibodies to SARS-CoV-2 in human serum. The assay performance has been evaluated at 10 hospitals. Clinical specificity was evaluated by measuring 972 hospitalized patients and 586 donors of a normal population. Clinical sensitivity was assessed on 513 confirmed cases of SARS-CoV-2 by RT-PCR.ResultsThe assays demonstrated satisfied assay precision with coefficient of variation of less than 4.45%. Inactivation of specimen did not affect assay measurement. SARS-CoV-2 IgM showed clinical specificity of 97.33 and 99.49% for hospitalized patients and the normal population respectively, and SARS-CoV-2 IgG showed clinical specificity of 97.43 and 99.15% respectively. SARS-CoV-2 IgM showed clinical sensitivity of 82.54, 92.93, and 84.62% before 7 days, 7–14 days, and after 14 days respectively, since onset of symptoms, and SARS-CoV-2 IgG showed clinical sensitivity of 80.95, 97.98, and 99.15% respectively at the same time points above.ConclusionsWe have developed fully automated immunoassays for detecting SARS-CoV-2 IgM and IgG antibodies in human serum. The assays demonstrated high clinical specificity and sensitivity, and add great value to nucleic acid testing in fighting against the global pandemic of the SARS-CoV-2 infection.

Sign in / Sign up

Export Citation Format

Share Document